3SBio Acquires Zhejiang Wansheng Pharmaceutical

Jul 24, 2015, 05:01 ET from 3SBio Inc.

SHENYANG, China, July 24, 2015 /PRNewswire/ --

  • Adds integrated small molecule drug R&D and manufacturing platform
  • Expands product offering for chronic kidney disease and oncology patients
  • Further addresses unmet medical needs in diabetes-related complications and dermatology
  • Increases group revenue and earnings

3SBio Inc., (HKEX:1530) ("3SBio" or 'the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd ("Zhejiang Wansheng") a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

"3SBio's proven capabilities in biologicals, combined with Zhejiang Wansheng's expertise in small molecule manufacturing, will provide the enlarged group with a flexible platform for addressing the unmet medical needs of patients and their healthcare professionals. Zhejiang Wansheng's current product portfolio includes six antidiabetic and hypertension products that are commonly used by chronic kidney disease patients, which will expand our products offering in the dialysis market in addition to our current nephrology portfolio. The acquisition also expands our portfolio of oncology drugs as Zhejiang Wansheng has six approved oncology products," commented Dr. Lou Jing, CEO and Chairman of 3SBio.

"The acquisition will further solidify 3SBio's leading position in nephrology and oncology as it also provides a platform for the company to proceed with the clinical development of over 12 small-molecule pipeline candidates in our core therapeutic areas using internal facilities and expertise, including HIF-PH inhibitor for anemia; cinacalcet hydrochloride for hyperparathyroidism; sevelamer carbonate for hyperphosphatemia; Colestilan for hyperphosphatemia and hypercholesteremia; DJ5 for autosomal dominant polycystic kidney disease (ADPKD); PEG-Irinotecanfor solid tumors; nadroparin calcium for blood clotting and thrombosis; and fondaparinux sodium for prophylaxis of deep vein thrombosis."

"It will also provide 3SBio with a solid base for expansion into the treatment of diabetes-related complications and dermatology, specialized markets where our academic marketing approach has the potential to build market-leading brands. Qiming Keli is one of few treatments for diabetic retinopathy, an ophthalmological disorder which affects approximately 34% of diabetic patients, or about 93 million globally, many of whom also suffer from kidney disease.  In dermatology, we will also seek further indications for fexofenadine hydrochloride, a treatment for chronic idiopathic urticaria, a skin condition common to many dialysis patients."

Mr. Luo Xie Long, CEO of Zhejiang Wansheng commented, "3SBio is a leading player in the biopharma industry in China. Joining the 3SBio group will expand our pipeline and commercial capability, and further drive the growth of Wansheng. We look forward to working on these opportunities with our 3SBio colleagues."

Zhejiang Wansheng currently has 55 product approvals addressing the oncology, diabetes, cardiovascular and dermatology areas.  It has 13 production lines capable of producing various drug delivery formats, including tablets, capsules, TCM granules, injections, tinctures, ointments and lotions, all recently GMP certified. Zhejiang Wansheng currently has approximately 630 employees, including a national salesforce of around 300.

Wansheng achieved turnover of RMB279.4 million and net profit after tax of RMB26.6 million for the year ended December 31, 2014.  After the acquisition, Zhejiang Wansheng will become a wholly-owned subsidiary of the Company and its results will be consolidated into the accounts of the Company. Additional financial details are available in the regulatory announcement submitted to the Stock Exchange of Hong Kong on July 24, 2015.

About 3SBio Inc.

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Since its founding in 1993, 3SBio's R&D efforts have resulted in four NDAs for biological medicines, including TPIAO, the first rhTPO approved worldwide.

3SBio has over 20 pipeline products with 14 of them developed as innovative class 1 products in China. Pipeline candidates include SSS07, an anti-TNF monoclonal antibody with a Phase I trial underway in China for the treatment of rheumatoid arthritis; NuPIAO/SSS06, a long-acting erythropoiesis-stimulating agent(ESA) for anemia associated with renal failure or chemotherapy and peri-operative blood cell mobilization which has entered into Phase I clinical trials in China; Uricase PEG-20/SSS11, a modified pegylated recombinant uricase from Candida utilis for the treatment of refractory gout and tumor lysis syndrome which has completed US Phase I trials; Leukotuximab/SSS19, an anti-CD43/JL-1 monoclonal antibody for treating acute leukemia; and Tanibirumab/SSS23, an anti-VEGFR2 monoclonal antibody for treating solid tumors.

A new state-of-the-art mammalian biological manufacturing facility in Shenyang is the first and only rhEPO facility in China that conforms to both Chinese and European pharmacopeia standards.

3SBio is China's leading specialist in nephrology and oncology supportive care with more than 600 sales professionals, covering over 3,000 hospitals in key cities supported by a nationwide network of 120 distributors and logistics providers. EPIAO has been the top selling rhEPO product in China since 2002 with a market share over 40%.

3SBio trades on the Stock Exchange of Hong Kong under code 1530.

Please visit www.3sbio.com for additional information.

SOURCE 3SBio Inc.



RELATED LINKS

http://www.3sbio.com